Salarius Pharmaceuticals (SLRX) Earnings Date, Estimates & Call Transcripts $0.55 -0.02 (-3.41%) Closing price 04:00 PM EasternExtended Trading$0.52 -0.03 (-5.27%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Salarius Pharmaceuticals Earnings Summary Salarius Pharmaceuticals issued Q2 2025 earnings on August 12, 2025, reporting an EPS of -$0.45. Salarius Pharmaceuticals currently has a trailing EPS of -$4.82Upcoming Q3 Earnings DateAug. 15Before Market OpensEstimatedQ2 2025 Earnings ResourcesQ2 2025 Earnings Report Quarterly Report (10-Q)SLRX Upcoming EarningsSalarius Pharmaceuticals' Q2 2025 earnings is scheduled for Friday, August 15, 2025, with a conference call scheduled on Tuesday, August 12, 2025 at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Powered by Get Salarius Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Salarius Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataSLRX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. Salarius Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$5.85-$5.85-$5.85Q2 20251-$5.85-$5.85-$5.85Q3 20251-$5.89-$5.89-$5.89Q4 20251-$5.89-$5.89-$5.89 Salarius Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 8/15/2025(Estimated)--------8/12/2025Q2 2025--$0.45--$0.45--5/14/2025Q1 2025-$2.40-$1.03+$1.37-$1.03--3/21/2025Q4 2024-$2.31-$0.66+$1.65-$0.66--8/9/2024--$53.60-$2.37+$51.23-$2.37--5/13/2024Q1 2024-$53.60-$3.28+$50.32-$0.41--3/22/2024Q4 2023-$8.08-$1.76+$6.32-$0.22--11/9/2023Q3 2023-$8.56-$5.20+$3.36-$0.65-- More Earnings Resources from MarketBeat Related Companies ENSC Earnings Date TCRT Earnings Date XBIO Earnings Date MTNB Earnings Date INM Earnings Date INDP Earnings Date DRMA Earnings Date CMND Earnings Date ADIL Earnings Date ALBT Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles CrowdStrike Faces Valuation Test Before Key Earnings ReportPost-Earnings, How Does D-Wave Stack Up Against Quantum Rivals?Why SoundHound AI's Earnings Show the Stock Can Move HigherAirbnb Beats Earnings, But the Growth Story Is Losing AltitudeDutch Bros Just Flipped the Script With a Massive Earnings BeatIs Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?Constellation Energy’s Earnings Beat Signals a New Era This page (NASDAQ:SLRX) was last updated on 8/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredElon Musk: “Nothing happens without this…”Lithium has fueled the EV boom, but another resource is even more critical. Without it, over 20 million electr...Behind the Markets | SponsoredTurn your "dead money" into $306+ monthly (starting this month)Turn your "dead money" into $306+ monthly (starting this month) I've been tracking a financial revolution t...Investors Alley | SponsoredMy shocking meeting in Washington, D.C.After a shocking discovery in D.C., Jeff Brown is revealing: President Trump’s “Project MAFA” Get a look...Brownstone Research | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Salarius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Salarius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access